Authors: MCLAUGHLIN P GRILLOLOPEZ AJ LINK BK LEVY R CZUCZMAN MS WILLIAMS ME HEYMAN MR BENCEBRUCKLER I WHITE CA CABANILLAS F JAIN V HO AD LISTER J WEY K SHEN D DALLAIRE BK

Citation: P. Mclaughlin et al., RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM, Journal of clinical oncology, 16(8), 1998, pp. 2825-2833

Authors: CZUCZMAN MS GRILLOLOPEZ AJ JONAS C GORDON L SALEH M WHITE CA VARNS C ROGERS J

Citation: Ms. Czuczman et al., IDEC-C2B8 AND CHOP CHEMOIMMUNOTHERAPY OF LOW-GRADE LYMPHOMA, Blood, 86(10), 1995, pp. 206-206

Authors: CZUCZMAN MS CLASS K SCHEINBERG DA

Citation: Ms. Czuczman et al., INTERLEUKIN-4 PRIMING ENHANCES A TARGET FOR HUMAN COMPLEMENT-MEDIATEDCYTOTOXICITY OF CLL, Leukemia, 7(7), 1993, pp. 1020-1025

Authors: CZUCZMAN MS STRAUS DJ DIVGI CR GRAHAM M GARINCHESA P FINN R MYERS J OLD LJ LARSON SM SCHEINBERG DA

Citation: Ms. Czuczman et al., PHASE-I DOSE-ESCALATION TRIAL OF IODINE 131-LABELED MONOCLONAL-ANTIBODY OKB7 IN PATIENTS WITH NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 11(10), 1993, pp. 2021-2029

Authors: CZUCZMAN MS GARINCHESA P LEMOLI RM SCHEINBERG DA

Citation: Ms. Czuczman et al., IGM MONOCLONAL-ANTIBODY JD118 RECOGNIZES AN INDUCIBLE ANTIGEN TARGET FOR HUMAN-COMPLEMENT-MEDIATED CYTOTOXICITY AGAINST NEOPLASTIC B-CELLS, Cancer immunology and immunotherapy, 36(6), 1993, pp. 387-396